Cidara Therapeutics (NASDAQ: CDTX) reported Q2 EPS of ($20.65), $20.51 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $6.95 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.